Key result
CIED-detected subclinical AF links to higher thromboembolic risk, but optimal anticoagulation remains unresolved.
Why the study?
The risk of thromboembolic events varies between patients with subclinical atrial fibrillation (SCAF) and clinically overt AF, leaving the role of anticoagulant therapy in SCAF unresolved.
Does anticoagulant therapy prevent thromboembolic events in patients with cardiac implantable electronic devices and subclinical atrial fibrillation?
Does anticoagulant therapy prevent thromboembolic events in patients with cardiac implantable electronic devices and subclinical atrial fibrillation?
This review highlights that while subclinical AF detected by CIEDs increases thromboembolic risk, routine anticoagulation is currently only considered for longer episodes (e.g., >24 hours) or high-risk patients, pending definitive trial data.
Answers are grounded in this paper and cite their sources.
Anticoagulation decisions for CIED-detected subclinical AF should remain individualized; leaves open optimal thresholds pending dedicated RCTs.
Screening for atrial fibrillation (AF) has attracted considerable attention recently. Of special interest are patients with cardiac implantable electronic devices (CIEDs) that allow for recording episodes of atrial arrhythmias of various durations, including asymptomatic ones, in which case they are referred to as subclinical atrial fibrillation (SCAF). The available data suggest that the risk of thromboembolic events varies between patients with SCAF and clinically overt AF. As of today, the question regarding anticoagulant therapy in patients with SCAF remains unresolved. The article presents an overview of previous and ongoing studies on this issue, as well as current guidelines on anticoagulant use in patients with SCAF and CIEDs.
No takes yet. Share an insight, caveat, or question.
Razina et al. (2023) conducted a review in Subclinical atrial fibrillation in patients with cardiac implantable electronic devices. Anticoagulant therapy was evaluated. Subclinical atrial fibrillation detected by cardiac implantable electronic devices is associated with an increased risk of thromboembolic events, but the optimal strategy for anticoagulant therapy remains unresolved.
Synapse has enriched 10 related papers. Consider them for comparative context: